Vasileios Eftychidis

Oct 27, 2024 | nature.com | Mohd Yaseen Malik |Fei Guo |Vasileios Eftychidis |Elena Eliseeva |Kerstin N. Timm |Stephan von Hörsten | +3 more

AbstractIdentifying initial triggering events in neurodegenerative disorders is critical to developing preventive therapies. In Huntington’s disease (HD), hyperdopaminergia—probably triggered by the dysfunction of the most affected neurons, indirect pathway spiny projection neurons (iSPNs)—is believed to induce hyperkinesia, an early stage HD symptom. However, how this change arises and contributes to HD pathogenesis is unclear.